Tumor necrosis factor ligand superfamily member 9 (4-1BBL), also known as 4-1BB ligand, CD137L, or TNFSF9, is a cytokine that binds to TNFRSF9. It serves as the high-affinity ligand for 4-1BB and ...

A pair of recent studies from the laboratory of Bin Zhang, MD, Ph.D., the Johanna Dobe Professor of Cancer Immunology, have ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving ...

which triggers 4-1BB signaling to stimulate NK cell proliferation and IFN-γ secretion. 4-1BBL is often co-administered with other cytokines to enhance the activation of NK cells. 3. Augment DC antigen ...

It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first-line metastatic gastric ...

First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in ...

A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors. This is an ASCO Meeting Abstract from ...

Researchers from Beigene (Beijing) Co. Ltd. have disclosed preclinical data for BGB-B167, a first-in-class immunoglobulin G (IgG)-based bispecific antibody (bsAb) targeting 4-1BB and CEA, being ...

AMP‑410 was discovered and developed using the Ampersand platform to block VEGF, which then triggers allosteric activation of the 4‑1BB pathway selectively in tumors. This novel molecular ...